Atezolizumab in addition to paclitaxel, carboplatin and bevacizumab for epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer – first-line
Atezolizumab in addition to carboplatin, paclitaxel and bevacizumab, is in clinical development for epithelial ovarian, fallopian tube or primary peritoneal cancer. Ovarian cancer includes a group of tumours that arise from the ovary. The most common type of ovarian cancer arises from the outside layer of cells on the surface of the ovary. Fallopian tube and primary peritoneal cancer are histologically equivalent diseases to ovarian cancer. These cancers are more often diagnosed at an advanced stage and treatment may consistent of surgery and/or chemotherapy.
Atezolizumab is a cancer medicine given by intravenous injection that works to enhance part of the immune system (T-cells) against tumours. Atezolizumab prevents DNA repair of cancer cells and is expected to enhance the activity of chemotherapy and targeted therapy such as bevacizumab when used in this combination. If licensed, atezolizumab in addition to bevacizumab, carboplatin and paclitaxel will offer an additional treatment option for women with newly diagnosed stage III or IV epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.